Randomized, Double Blind, Placebo Controlled Clinical Trial of Ivermectin For Post Exposure Prophylaxis For COVID-19 Infection Among Close Contacts
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 50
- 试验地点
- 10
- 主要终点
- Number of Covid-19 cases
研究概览
简要总结
Post exposure prophylaxis of healthy contacts is among the measures used for outbreak control of several infectious diseases (e.g., pandemic influenza). No agent is known to be effective in preventing COVID-19, but Ivermectin is one of the drugs that have shown antiviral activity against SARS-CoV-2 in the laboratory. This study aims to evaluate the effect of post exposure prophylaxis with Ivermectin after exposure to COVID-19 among the asymptomatic close contacts.
详细描述
Primary Objective:
To assess the efficacy of Ivermectin as post exposure prophylaxis in asymptomatic adults (≥18 years of age) who had close-contact exposure to a confirmed case of COVID-19 patient
Secondary Objectives:
- To compare the viral load (using CT value reading) among close contacts who become positive COVID-19 during follow up period between the Ivermectin and placebo group
- To assess the adverse effects of Ivermectin within 7 days after each dose
Study Population and Sampel Size Asymptomatic adults (≥18 years of age) who had recent history (less than 5 days) of close contact exposure to a confirmed COVID-19 positive patient as per the definition by CDC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
盲法说明
This is a randomized, double blind, placebo controlled clinical trial evaluating the effect of Ivermectin for post exposure prophylaxis among close contacts of COVID-19 positive case patient as an index case.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Asymptomatic individuals exposed to a confirmed positive COVID-19 case within 5 days from the study recruitment day (include household, workplace and social close contact)
- •Aged ≥18 years; male or female
- •No fever with temperature less than 37.5ºC
- •RTK Ag for COVID-19 is negative on the recruitment day.
- •For subject who had received COVID-19 vaccination:
- •Any primary series vaccine (eg: Pfizer, Sinovac, AstraZeneca etc) : past 90 days after the second dose
- •Any booster vaccine: past 90 days after the booster dose
- •In women of childbearing potential (18-55 years old), negative pregnancy test and agree to use any contraceptive method up to 7 days after the second dose of IP administration
- •Have access to video and phone call
- •Willing to take 2 doses of study medication (2 days apart between Dose 1 and Dose 2)
- •Willing to comply with all study procedures
- •Able to provide written informed consent
排除标准
- •Unable to take drugs by mouth
- •History of positive confirmed COVID-19 infection within past 3 months
- •Involved in any COVID-19 vaccine clinical trial
- •Patients with suspected concomitant bacterial, fungal infections, concurrent congestive heart failure prior to initiation of study drug
- •Known case of liver disease (any severity)
- •Alcohol intake more than recommended (2 drinks or more in a day for men and 1 drink or more in a day for women)
- •Mal-absorption syndrome or other clinically significant gastrointestinal disease that may affect absorption of the study drug (non-correctable vomiting, diarrhea, ulcerative colitis, and others).
- •Pregnant or nursing/breastfeeding women or women planning for pregnancy.
- •Female patients who cannot consent to contraceptive use (any method) from the start of IP administration to 7 days after the second dose of IP administration
- •Male patients whose partner cannot agree to use the contraception method as in 9)
- •Patients with a history of gout or on treatment for gout or hyperuricemia
- •Patients receiving immunosuppressant
- •Patients who have previously received Ivermectin.
- •Patients who are not able to provide written consent.
- •Other patients judged ineligible by the principal investigator or sub-investigator
研究组 & 干预措施
Treatment group:
Ivermectin 0.4 mg/kg/day (maximum 24 mg)
干预措施: Ivermectin (Drug)
Control group
Placebo-inactive substance
干预措施: Placebo (Other)
结局指标
主要结局
Number of Covid-19 cases
时间窗: 8 weeks
Comparison of the number of confirmed COVID-19 cases among the close contacts after exposure to a confirmed case of COVID-19 patient in Ivermectin and placebo group
次要结局
- CT value in Covid-19(14 days)